Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

Next Previous
Trial Profile

Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirtazapine (Primary)
  • Indications Anxiety
  • Focus Therapeutic Use

Most Recent Events

  • 07 Sep 2018 Status changed from recruiting to completed.
  • 14 Mar 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018 as per ClinicalTrials.gov record.
  • 14 Mar 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top